Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135629 | 1.00 | IGF1R (0.79) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5137937 | 0.96 | IGF1R (0.76) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5137939 | 0.96 | IGF1R (0.76) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6095273 | 0.94 | IGF1R (0.69) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6095304 | 0.94 | IGF1R (0.69) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6096682 | 0.93 | IGF1R (0.68) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6096652 | 0.93 | IGF1R (0.68) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6096078 | 0.92 | IGF1R (0.66) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6096086 | 0.92 | IGF1R (0.66) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6095632 | 0.92 | IGF1R (0.68) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381598-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1381598-A1 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002079192-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | IGF1R 216/4885CYP3A4 2334/4885CYP1A2 1415/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | IGF1R 302/4885CYP3A4 2522/4885CYP1A2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.